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Background: Nevirapine is metabolized by CYP2B6 and polymorphisms within the CYP2B6 gene partly explain
inter-patient variability in pharmacokinetics. The aim of this study was to model the complex relationship
between nevirapine exposure, weight and genetics (based on combined analysis of CYP2B6 516G.T and
983T.C single nucleotide polymorphisms).
Methods: Non-linear mixed-effects modelling was used to estimate pharmacokinetic parameters from 275
patients. Simulations of the nevirapine concentration proﬁle were performed with dosing regimens of
200 mg twice daily and 400 mg once daily for individuals with body weights of 50, 70 and 90 kg in combination
with CYP2B6 genetic variation.
Results: A one-compartment model with ﬁrst-order absorption best described the data. Population clearance
was 3.5 L/h with inter-patient variability of 24.6%. 516T homozygosity and 983C heterozygosity were associ-
ated with 37% and 40% lower clearance, respectively. Body weight was the only signiﬁcant demographic
factor inﬂuencing clearance, which increased by 5% for every 10 kg increase. For individuals with higher
body weight, once-daily nevirapine was associated with a greater risk of sub-therapeutic drug exposure than
a twice-daily regimen. This risk was offset in individuals who were 516T homozygous or 983C heterozygous
in which drug exposure was optimal for .95% of patients with body weight of ≤70 kg.
Conclusions: The data suggest that a 400 mg once-dailydose could be implemented in accordance with CYP2B6
polymorphism and body weight. However, the use of nevirapine once daily (immediate release; off-label) in
the absence of therapeutic drug monitoring is not recommended due to the risk of inadequate exposure to
nevirapine in a high proportion of patients. There are different considerations for the extended-release formu-
lation (nevirapine XR) that demonstrate minimal peak-to-trough ﬂuctuations in plasma nevirapine levels.
Keywords: CYP2B6, body weight, antiretroviral agents, dose selection, NONMEM
Introduction
Nevirapine-based antiretroviral combinations are ﬁrst-line regi-
mens for HIV-1 infection in most resource-poor settings,
1 due to
relatively low cost, manageable pill burden and excellent efﬁcacy.
2
However, the use of nevirapine is limited by two main factors: an
immune-mediated hypersensitivity reaction that manifests as
hepatotoxicity, fever and/or rash;
3,4 and a fragile genetic barrier
to the development of drug resistance.
5 Nevirapine is metabolized
primarily by the cytochrome P450 3A4 and 2B6 enzymes into its
major metabolites 2-hydroxynevirapine and 3-hydroxynevirapine,
respectively. There is also a minor contribution from CYP3A5.
6
These isoenzymes are characterized by wide inter-individual
variability in expression and activity in human liver microsomes
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7,8 The 516G.T single nucleotide polymorphism (SNP) in
CYP2B6 has been reported to have a major impact on the
pharmacokinetics and pharmacodynamics of efavirenz.
9 Some
studies have also shown that 516G.T is associated with
nevirapine plasma concentration.
9–12 Recently, we reported
that heterozygosity for the 983T.C SNP was associated with sig-
niﬁcantly higher nevirapine plasma levels in black patients.
13
Previous studies have found body weight, ethnicity, gender
and underlying liver disease to be important in explaining nevir-
apine pharmacokinetics.
14 Several studies have examined the
relationship between exposure to nevirapine and virological
response. The risk of virological failure in patients who receive
nevirapine-based antiretroviral therapy increases 5-fold when
nevirapine plasma concentrations are ,3.0 mg/L compared
with patients with higher concentrations.
15,16 As a result, a
trough concentration (Ctrough) target of 3.0 mg/L has been pro-
posed as a minimum effective concentration (MEC).
17
The recommended dose of nevirapine is 200 mg once daily
for the ﬁrst 2 weeks, followed by 200 mg twice daily.
18
However, the pharmacokinetic proﬁle of nevirapine, in particular
its long half-life, may allow once-daily dosing at 400 mg daily
(following the 200 mg daily lead-in period). Several studies
have shown that 400 mg once-daily dosing gives a similar virolo-
gical and immunological response to a 200 mg twice-daily
regimen.
14 However, van Heeswijk et al.
19 reported that nevira-
pine Ctrough were lower for the once-daily regimen, which might
result in an increased risk of developing drug resistance in vulner-
able patients.
Identifying sources of variability in nevirapine pharmacoki-
netics could therefore be of importance in the clinical manage-
ment of HIV infection and may aid in optimal dosage
selection. The purpose of this study was to develop and
validate a population pharmacokinetic model for nevirapine
and identify covariates that affect pharmacokinetic variability.
In particular, the inﬂuence of the CYP2B6 516G.T and
983T.C SNPs and their effect on nevirapine trough plasma
concentrations for twice- and once-daily nevirapine regimens
were evaluated.
Methods
Patients
A total of 113 HIV-positive patients on nevirapine-based regimens
(38 patients receiving 400 mg once daily) were recruited from the
Department of HIV Medicine, Royal Free NHS Trust, London and 162
HIV-positive patients were recruited from the German Competence
Network for HIV/AIDS (KompNet Cohort) (200 mg twice daily). The
ﬁrst cohort included 11 patients with six blood samples collected in
the dosing interval, 9 patients who had blood collection on two
different occasions and 102 patients who had one random blood
drawn. In the second cohort, all patients had one random blood
drawn. Plasma was obtained and stored at 2808C before analysis.
All the patients had an HIV viral load of ,50 copies/mL at the time
of sampling. Associations of CYP2B6 polymorphisms with nevirapine
plasma concentrations in these cohorts have previously been pub-
lished.
10,13 Patients were only recruited if they had achieved
steady-state on a nevirapine-based regimen, in combination with
two nucleoside reverse transcriptase inhibitors (NRTIs) or one NRTI
plus one nucleotide reverse transcriptase inhibitor and were known
to be fully compliant. Patients on a concomitant ritonavir-boosted
protease inhibitor and other known major interacting drugs were
excluded. All blood sampling was performed after written informed
consent had been obtained in accordance with local ethics committee
indications. The following covariates were available: age; gender; body
weight; and pharmacogenetics (CYP2B6 516G.T and 983T.C).
Genotyping
Total genomic DNA was isolated using the QIAamp DNA mini kit accord-
ing to the manufacturer’s instructions. Following extraction, purity was
assessed by comparing the A260 and A280 ratio. DNA was quantiﬁed
using PicoGreen
w dsDNA Quantitation Reagent (Molecular Probes, CA,
USA) and normalized to 20 ng/mL. Pre-ampliﬁcation for exon 4, exon 9
and exons 7 and 8 (combined) was ﬁrst conducted to discriminate
from the CYP2B6 pseudogene (CYP2B7) by modiﬁcation of previously
reported methods. Genotyping for 516G.T and 983T.C was then per-
formed on the resultant amplicons by real-time PCR allelic discrimination
using standard methodology (958C for 15 min followed by 40 cycles of
958C for 15 s and 608C for 1 min) in a DNA Engine Opticon
w 2 system
(MJ Research Inc., USA). Full PCR conditions as well as primer and
probe sequences are available on request.
Quantiﬁcation of drug levels
Plasma obtained from blood samples was heat inactivated and nevira-
pine concentrations were determined using HPLC with UV detection
using validated assays as previously described.
20 The lower limit of
quantiﬁcation of nevirapine was taken as the lowest point on the stan-
dard curve (100 ng/mL). Intra-assay and inter-assay coefﬁcients of vari-
ation at 100 ng/mL were 6.7% and 8.2%, respectively. The Liverpool
laboratory participates in an external quality assurance scheme (KKGT,
The Hague, The Netherlands).
Population pharmacokinetic analysis
The pharmacokinetic model was developed using NONMEM
w (ICON,
version VI 2.0) installed under nmqual (Metrum institute).
21,22 Data pro-
cessing and graphical analyses were done using Microsoft
w Ofﬁce Excel
2007 for Windows (Microsoft Corporation, Redmond, WA, USA).
The model building strategy was as follows: one- and two-
compartment models with ﬁrst- or zero-order absorption without and
with lag time were ﬁtted to the data using the ﬁrst-order conditional
method of estimation. Proportional, additional and combined pro-
portional and additional error models were evaluated to describe residual
variability. Inter-occasion variability was also tested. The minimal objec-
tive function value (OFV; equal to 22 log likelihood) was used as a
goodness-of-ﬁt metric with a decrease of 3.84 corresponding to a stat-
istically signiﬁcant difference between models (P¼0.05, x
2 distribution,
one degree of freedom). Residual plots were also examined. Once the
appropriate structural model was established, the following covariates
were explored: body weight; age; gender; ethnicity; and CYP2B6
516G.T and 983T.C polymorphisms. Dichotomous and continuous
variables, here deﬁned as X, were introduced into the model using the fol-
lowing parameterizations, respectively:
TVCL = u0 ×( 1 + u1 × X)( 1)
TVCL = u0 + u1 ×( X−median value)( 2)
where TVCL is the typical value of nevirapine apparent clearance (CL/F) of
the population; in equation 1 u0 is the value of CL/F for the individual’s
X¼0, and u1 is the relative difference in CL/F for the individual’s X¼1.
In equation 2, u0 is the typical CL/F at the median body weight, u1 is
the change in CL/F per kg, and X is the continuous variable (the
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JACindividual’s body weight or age). Graphical methods were used to explore
the relationship of covariates versus individual predicted pharmacokinetic
parameters. Each covariate was introduced separately into the model
and only retained if inclusion in the model produced a statistically signiﬁ-
cant decrease in OFVof 3.84 (P≤0.05). A backwards elimination step was
then carried out once all relevant covariates were incorporated and cov-
ariates were retained if their removal from the model produced a signiﬁ-
cant increase in OFV (.6.63 points; P≤0.01, x
2 distribution, one degree
of freedom).
To perform a visual predictive check, 1000 datasets were simulated
using the parameter estimates deﬁned by the ﬁnal model with the SIMU-
LATION SUBPROBLEMS option of NONMEM
w. Datasets were simulated for
nevirapine 200 mg twice daily and 400 mg once daily. From the simu-
lated data, 90% prediction intervals (PIs) (P5–P95) for each regimen
were constructed. Observed data from the original dataset were super-
imposed for both regimens. At least 90% of data points within the PI
(5% above and below) was indicative of an adequate model.
In addition, in order to conﬁrm the stability and robustness of the
model, bootstrap re-sampling was used. Bootstrapping was performed
with the software package Perl-speaks-NONMEM 5.1.
23 The median
values and 90% conﬁdence intervals for the parameter estimates were
obtained from 200 bootstrap replicates of the original dataset and com-
pared with the original population parameters.
To investigate the effect of genetics and body weight on nevirapine
Ctrough with 400 mg once-daily and 200 mg twice-daily doses,
simulated data of nevirapine administered for both regimens were
generated; 90% PIs of the simulated concentrations for each category
were plotted.
Results
Population analysis was performed with 406 drug concentrations
from 275 patients receiving nevirapine-containing regimens for
≥4 weeks. Three patients with peak concentrations ,1 mg/L
were excluded due to suspected non-adherence to therapy.
Their exclusion improved the model ﬁt, thus they were not
included in the ﬁnal model. The demographic characteristics of
the patients are shown in Table 1.
Nevirapine pharmacokinetics of 272 HIV-positive patients
with 403 drug concentrations were best described by a one-
compartment model with ﬁrst-order absorption and ﬁrst-order
elimination. A one-compartment model with zero-order absorp-
tion or a two-compartment model did not improve the ﬁt. In the
model, residual variability was best described by a proportional
structure; the inclusion of an additive structure did not improve
the model. Inter-individual random effects were described by
an exponential model that was supported only for CL/F. The
introduction of an absorption lag time did not improve the
model ﬁt. In the basic model the mean population estimates
for CL/F, apparent volume of distribution (V/F) and absorption
constant (ka) were 3.14 L/h, 153 L and 1.25 h
21, respectively;
the inter-individual variability in CL/F expressed by the coefﬁcient
of variation (CV) was 0.13. The residual variability was 0.0085.
A total of six covariates (weight, age, gender, ethnicity, CYP2B6
516G.Tand 983T.C) were analysed using a stepwise backward
elimination. CL/F signiﬁcantly (P,0.001) correlated with three
covariates: weight; CYP2B6 516G.T; and 983T.C. The mean
population estimate for CL/F was 3.5 L/h; the ﬁnal covariate
model is detailed in Table 2. Inclusion of body weight resulted in
an improvement of the goodness of the ﬁt (DOFV¼9.7), a slight
decrease in inter-individual variability of 2% and CL/F increased
Table 2. Nevirapine (NVP) ﬁnal parameter estimates and standard errors obtained from the ﬁnal population pharmacokinetic model
Parameter Basic model (RSE %) Final model (RSE %)
Bootstrapped median (90% PI)
in the ﬁnal model
CL/F (L/h) 3.14 (2.4) 3.51 (3.0) 3.5 (3.3, 3.7)
V/F (L) 153 (8.7) 150 (8.7) 148.5 (127.3, 172.6)
ka (h
21) 1.25 (22.5) 1.20 (22) 1.22 (0.7, 1.67)
IIV CL/F (%) 36 (10.6) 31 (10.8) 32 (29, 34)
Residual error
proportional (%) 9.2 (11.0) 9.2 (10.8) 10.8 (7.9, 13)
u associated with BW on NVP CL/F 0.018 (32.8) 0.0183 (0.008, 0.027)
u associated with 516GTon NVP CL/F 20.5 (27.3) 20.5235 (20.7, 20.3)
u associated with 516TTon NVP CL/F 21.3 (16.7) 21.3 (21.7, 20.9)
u associated with 983TC on NVP CL/F 21.4 (13.2) 21.38 (21.7, 20.3)
RSE, relative standard error; IIV, inter-individual variability; BW, body weight; 516GT, heterozygosity; 516TT, homozygosity; 983TC, heterozygosity.
RSE deﬁned as (SEestimate/estimate)×100.
Final pharmacokinetics model TVCL¼u0+u1×(BW2median weight)+u2×X516GT+u3×X516TT+u4×X983TC.
Table 1. Summary of patient demographics and baseline clinical
characteristics of patients included in the pharmacokinetic modelling
Study participants, n (M/F) 275 (161/114)
200 mg twice daily, n 237
400 mg once daily, n 38
Age (years), median (range) 42 (18–82)
Weight (kg), median (range) 72.5 (47–132)
Caucasian ethnicity, n (%) 183 (66.5)
Black ethnicity, n (%) 92 (33.5)
516GT, n (%) 126 (46)
516TT, n (%) 19 (7)
983TC, n (%) 9 (3)
n, number of patients; M, male; F, female; 516GT, heterozygous patients;
516TT, homozygous patients; 983TC, heterozygous patients.
Schipani et al.
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graphic covariates proved to be statistically signiﬁcant.
The impact on CL/F for each variant genotype of 516G.Tand
983T.C was expressed as CL¼CL0+u1×HET+u2×HOM, where
HETandHOMindicategenotypicstatusbeingequalto1forhetero-
zygous and homozygous individuals, respectively, and 0 for the
wild-type patients. CL0 is the typical value of CL/F for individuals
carrying wild-type alleles. The current dataset had only wild-type
and heterozygous individuals for CYP2B6 983T.C. To date, no
homozygotes for this polymorphism have been described. In
subjects who were heterozygous for 516GT CL/F decreased by
0.5 L/h,andinhomozygotesthemodelshowedamoreconsistent
decrease in CL/Fof 1.3 L/h. Patients with the 983TC genotype also
showeda signiﬁcantdecreaseinCL/Fof1.4 L/h. A summaryofthe
ﬁnal population estimates is presented in Table 2; the inclusion of
the genotypes decreased CL/F inter-individual variability by 4%.
The ﬁnal model was carried out using the following equation:
TVCL¼u0+u1×(BW272.5)+u2×X516GT+u3×X516TT+u4×X983TC.
The diagnostic plots for the ﬁnal model suggested that predicted
and observed data were in agreement (Figure 1). The individual
weighted residuals did not reﬂect any particular systematic
trends.
A 90% PI was generated from 1000 simulations for nevirapine
200 mg twice daily and 400 mg once daily, with the covariate
values of those individuals used in the building process
(Figure 2). Observed data from patients used in the model build-
ing process were superimposed onto the PI. The proportion of
nevirapine concentrations .P95 was 5.3% and ,P5 was 2.6%
in patients receiving 400 mg of nevirapine once daily (n¼38),
and 2% were .P95 and 2.5% were ,P5 in patients receiving
200 mg of nevirapine twice daily (n¼362). These ﬁndings
suggested that overall the ﬁnal model performed adequately.
In addition, from the original dataset, 200 bootstrap replicate
datasets were generated and used to evaluate the stability of
the ﬁnal model. The median values of the parameter estimates
from the bootstrapping were very similar to the mean population
estimates for the ﬁnal model (Table 2). The 90% PI for the par-
ameter estimates obtained from the bootstrap procedure
revealed adequate estimation of the pharmacokinetic
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Figure 1. Goodness of ﬁt plots for the ﬁnal pharmacokinetic model
illustrating (a) population predictions of nevirapine versus observed
concentrations, (b) individual predictions of nevirapine versus observed
concentrations (where the continuous lines show the lines of unity and
the broken lines show the lines of regression) and (c) weighted
residuals versus time post-dose (where the continuous line shows the
line at an ordinate value of zero).
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Figure 2. Ninety percent PIs determined from simulated data of
nevirapine (a) 200 mg twice daily and (b) 400 mg once daily. The
mean population prediction is shown as a continuous line and the 90%
PI is shown as a broken line. NVP, nevirapine.
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Figure 3. Steady-state 90% PI (P5–P95) determined from simulated data of nevirapine (NVP) administered at different doses. The mean population
prediction (continuous thick line) and the 90% PI (grey area) are represented for each category. The broken horizontal line is at an ordinate value of
3 mg/L (proposed MEC). (a) Steady-state NVP concentrations predicted at a 200 mg twice-daily dose. Proportion below the MEC: 516GG, 50 kg 12%,
70 kg 19% and 90 kg 28%; 516TT, 50 kg 0.3%, 70 kg 1% and 90 kg 3%; and 983TC, 50 kg 0.2%, 70 kg 1% and 90 kg 2%. (b) Steady-state NVP
concentrations predicted at a 400 mg once-daily dose. Proportion below the MEC: 516GG, 50 kg 20%, 70 kg 31% and 90 kg 43%; 516TT, 50 kg
1%, 70 kg 3% and 90 kg 7%; and 983TC, 50 kg 0.6%, 70 kg 2% and 90 kg 6%.
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the ﬁnal model.
In order to evaluate the combined clinical impact of the phar-
macogenetic factors and body weight, simulated concentration–
time courses of a single dose of nevirapine (200 mg twice daily
and 400 mg once daily at steady-state to typical individuals
with body weights of 50 kg, 70 kg and 90 kg were performed.
The simulations were carried out ﬁrstly with a population of indi-
viduals homozygous for the common alleles (516GG and 983TT)
and secondly with the variant alleles 516TTand 983TC (Figure 3).
For 400 mg once-daily simulations, the proportions of individuals
with potentially sub-therapeutic (i.e. ,MEC) Ctrough were 516TT
versus 516GG: 50 kg (1% versus 20%); 70 kg (3% versus 31%);
and 90 kg (7% versus 43%). For 200 mg twice-daily simulations
these proportions were: 50 kg (0.3% versus 12%); 70 kg (1%
versus 19%); and 90 kg (3% versus 28%). Similarly, proportions
for potentially sub-therapeutic Ctrough for 983TC versus 983TT
individuals were: 50 kg (0.6% versus 20%); 70 kg (2% versus
31%); and 90 kg (6% versus 43%). For 200 mg twice-daily simu-
lations these proportions were: 50 kg (0.2% versus 12%); 70 kg
(1% versus 19%); and 90 kg (2% versus 28%).
Discussion
The non-NRTIs, efavirenz and nevirapine, are extensively used as
part of a ﬁrst-line regimen or for simpliﬁcation of highly active
antiretroviral therapy due to their simplicity, tolerability and efﬁ-
cacy.
9 Both drugs are metabolized by CYP2B6, a highly poly-
morphic enzyme with numerous SNPs and associated
haplotypes.
24 The possible signiﬁcance of CYP2B6 pharmacoge-
netics for clinical drug treatment is emerging, with consistent
pharmacokinetic effects demonstrated for efavirenz.
25–27 It has
recently been shown that CYP2B6 can also play an important
role in the biotransformation of nevirapine.
9–11,13,25,28
This study examined the impact of the CYP2B6 516G.T and
983T.C SNPs on nevirapine clearance and simulated Ctrough
obtained from once-daily and twice-daily nevirapine regimens.
The model that best described nevirapine pharmacokinetics was
aone-compartmentmodelwithﬁrst-orderabsorptionandelimin-
ation, and the model estimate parameters are consistent with
values previously published.
14,19,29,30 The volume of distribution
was slightly greater compared with a previous study, although
still in range.
14 This may be due to the relatively high body
weightofthepatients(averagebodyweight75 kg)andnevirapine
being lipophilic and weakly basic. The drug might be taken up by
adiposetissues,thusresultinginalargeapparentvolumeofdistri-
bution. Inter-individual variability was identiﬁed only for CL/F. The
dataset included mainly sparse data and a limited number of
samples in the absorption phase. This could explain the lack of
inter-individual variability for ka. This factor may also affect the
determination of inter-individual variability for V/F.
31
Body weight was the only demographic covariate signiﬁcantly
related to CL/F, which increased by 5% with body weight increase
of 10 kg. The inclusion of CYP2B6 genetics also improved the
model ﬁt. The impact of 516G.T was tested including heterozy-
gous and homozygous subjects, showing that both genotypes
inﬂuenced CL/F to a signiﬁcant extent (DOFV¼227.8). Particu-
larly signiﬁcant was the effect of the 516TT genotype, which
decreased CL/F by 37%. Importantly, there was a gene–dose
effect with 516GT decreasing CL/F by 15% compared with the
516GG genotype. CYP2B6 516G.T is one of the most commonly
occurring variants, leading to a Gln172His change in amino acid.
Although, it is not directly in the protein active site, residue 172
along with additional nearby SNP residues (in linkage disequili-
brium), could affect ligand binding,
32 altering the size and
ﬂexibility of the active site. A recent study by Chou et al.,
12 also
evaluated the impact of the CYP2B6 516G.T polymorphism in
a Cambodian population. The study showed a decrease in clear-
ance from 516GG to the 516GT and 516TT genotypes of 11%
and 37%, respectively. The results of this study and the current
analysis indicate a consistent effect of CYP2B6 516G.T poly-
morphism in different populations.
The impact of 983T.C was also statistically signiﬁcant
(DOFV¼29.4), with heterozygotes for this allele having a 40%
lower CL/F. This SNP usually occurs as part of the *18 haplotype.
Recombinant expression of the variant, in which the highly con-
served hydrophobic Ile at position 328 within the J helix is
changed into Thr, showed undetectable expression and activity
in COS-1 cells.
24 This suggests that the resulting effect of this
variant could be a loss of protein function resulting from a hydro-
phobicity change from Ile to the polar Thr.
33 These alterations
might explain the high impact of 983TC on CL/F.
The total decrease in OFV after the inclusion of the SNPs was
32.2, thus 516G.T and 983T.C were included in the ﬁnal
model. Overall, these results are in agreement with other
studies previously published.
10,13 In contrast, in a recent study,
Haas et al.
34 did not ﬁnd any association between CYP2B6
516G/T and nevirapine plasma concentrations. However, this
lack of association was observed in a single-dose study of nevir-
apine pharmacokinetics, prior to auto-induction of the enzymes
and achievement of steady-state.
Nevirapine pharmacokinetics permits a once-daily regimen,
and several clinical trials have evaluated once-daily adminis-
tration. The 2NN study
35 showed that total drug exposure
(AUC24), was comparable in once-daily and twice-daily adminis-
trations. However, van Heeswijk et al.
19 showed a signiﬁcant
difference in Ctrough levels, which were lower for the once-daily
regimen. Similar ﬁndings were reported by Molto et al.,
30 who
estimated nevirapine Ctrough for the two regimens using a popu-
lation pharmacokinetic approach accounting for body weight.
However, the impact of body weight on CL/F was more than
double compared with this study (change in CL/F with a body
weight increase of 10 kg, 0.4 versus 0.18 L/h). Also, in the
study of Molto et al.
30 the CL/F is relatively low (2.95 L/h),
which resulted in a smaller proportion of simulated subjects
with sub-therapeutic plasma concentrations compared with
the present study. Cooper and van Heeswijk
14 indicated that
the interquartile range of CL/F was 2.80–4.21 L/h and de Maat
et al.
29 indicated a change in CL/F of 0.14 L/h with a body
weight increase of 10 kg, which are similar to the values pre-
sented in this report. A limitation of the present study is that
the majority of the samples are from patients recruited for thera-
peutic drug monitoring (TDM) and with limited information on
diseases status. TDM patients are often selected (e.g. non-
adherence, investigational dosing regimens, unfavourable drug
interaction, suspected toxicity) and this could have impacted
on the percentage (9.8%) of patients on 200 mg twice daily
being below the MEC. These factors and a relatively limited
number of patients on 400 mg once daily may have contributed
Population PK and pharmacogenetics of nevirapine twice and once daily
1337
JACto affect the model predictions. However, the predicted par-
ameters were in the range of a previous study.
14
Molto et al.
30 and van Heeswijk et al.
19 both suggested that
the once-daily regimen might place patients at risk of sub-
therapeutic concentrations at the end of the dose interval
(Ctrough,3 mg/L), increasing the risk of the development of
drug resistance. More recently, data have been presented on a
new extended-release formulation of nevirapine dosed once
daily (nevirapine XR). In the VERxVE trial there was non-inferior
efﬁcacy of nevirapine XR compared with the immediate-release
twice-daily formulation.
36 Nevirapine XR gave a ‘ﬂatter’ plasma
concentration–time curve than twice-daily dosing.
In the present study a population pharmacokinetic model
was used to assess the complex relationship between drug
exposure, weight and genetics (based on combined analysis
of CYP2B6 516G.T and 983T.C SNPs). Simulation of drug
exposure was performed for different groups across a range
of body weights and genetics, for twice- and once-daily nevir-
apine regimens. Using a mixed-effects modelling approach
with data from two distinct cohorts the potential utility of
pharmacogenetic testing in optimizing dose based on body
weight was explored.
For individuals with higher body weight, once-daily nevirapine
was associated with a greater risk of sub-therapeutic drug
exposure than a twice-daily regimen. This risk was offset in indi-
viduals who were 516T homozygous or 983C heterozygous in
which drug exposure was optimal for .95% of patients with a
body weight of ≤70 kg. This individualized approach, integrating
population pharmacokinetic analysis, weight-based dosing and
pharmacogenetics, could also be applied to dosing strategy in
populations. For example, twice-daily dosing is likely to be
more robust in individuals weighing ≥90 kg for a population
with a low frequency of these CYP2B6 variants (e.g. Caucasian).
In contrast, black Africans even those weighing ≥90 kg are
more likely to achieve an adequate drug level with once-daily
nevirapine dosing, although there will still be some individuals
who remain sub-therapeutic. This is important since the nucleo-
side backbone of WHO ﬁrst-line regimens is moving away from
stavudine towards once-daily dosing that could be
co-formulated with nevirapine.
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